Publications by authors named "E Vegh"
Introduction: Erdheim-Chester disease (ECD) is a rare disease that belongs to the group of Dendritic and histiocytic neoplasms. Only 2000 cases have been reported worldwide. It can present with a wide range of symptoms, making a differential diagnosis especially difficult.
View Article and Find Full Text PDFArticle Synopsis
- - Cardiovascular issues are common in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and natural autoantibodies (nAAbs) play a role in inflammation and atherosclerosis linked to these conditions.
- - A study involving 53 patients treated with anti-TNF therapies over a year found improvements in vascular function and stabilization of vascular thickness, while also noting changes in nAAb levels.
- - The research suggests that nAAbs may independently affect autoimmunity and vascular health in biologic-treated patients, highlighting a complex relationship between arthritis, inflammation, and cardiovascular risks.
Motivation: Zooarchaeology by Mass Spectrometry (ZooMS) is a palaeoproteomics method for the taxonomic determination of collagen, which traditionally involves challenging manual spectra analysis with limitations in quantitative results. As the ZooMS reference database expands, a faster and reproducible identification tool is necessary. Here we present SpecieScan, an open-access algorithm for automating taxa identification from raw MALDI-ToF mass spectrometry (MS) data.
View Article and Find Full Text PDFIn our present study, we aimed to assess the effects of anti-TNF therapy on periodontal condition in a mixed cohort of patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Moreover, we wished to determine whether the baseline dental condition of these patients would affect response to biological therapy. A cohort of 24 arthritis patients was consecutively recruited before starting anti-TNFα therapy.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how 12 months of tofacitinib treatment affects the Renin-Angiotensin-Aldosterone system (RAAS) in rheumatoid arthritis patients, particularly focusing on angiotensin converting enzyme (ACE) and ACE2 levels.
- Twenty-six RA patients completed the study, revealing that tofacitinib treatment significantly increased serum ACE levels and the ACE/ACE2 ratio after one year, while ACE2 activity only showed a temporary increase at six months.
- The results suggest a link between baseline inflammation, disease duration, and specific biomarkers (like rheumatoid factor) with changes in the ACE/ACE2 ratio during the treatment period.